Weekly healthcare intelligenceRegulation · Enforcement · Government payersAll editions →
Complete report · Compliance Sweep

Compliance Sweep, November 15, 2026

Published November 15, 2026Coverage November 8–14, 2026, Pacific

Read this edition’s coverage limitations ↓

Executive triage

This week. Three device actions call for an inventory check in hospitals that stock the products. Arrow International, a subsidiary of Teleflex, told customers on November 5 to stop using, quarantine and return certain products with Spring Wire Guide components, because the hydrophilic coating may swell unevenly, clump and potentially detach, which could raise the risk of emboli. Intersurgical told customers on November 3 to quarantine and return listed lots of its 22mm Smoothbore breathing tubes and systems, some made with too little solvent to secure the soft connectors; a connector that disconnects during use could cause loss of ventilation. FDA's Enforcement Report for the week of November 11 lists a Class I recall of four lots of the Edwards Commander M mitral valve delivery system for a manufacturing issue which may result in balloon rupture. Medline says it has received reports related to seven deaths and 35 serious injuries associated with the fire hazard and entrapment issues in its bed recall; the continued-use instructions are unchanged. The Cutting Administrative Requirements for Excellence in Patient Care (CARE) proposed rule was published on November 10: comments are assured consideration if received by January 11, 2027, and CMS's November 5 fact sheet describes the obstetric requirements it would remove as otherwise effective January 1, 2027. Federal independent dispute resolution (IDR) web forms moved into the IDR Gateway on November 13, and after January 15, 2027 a dispute cannot be started outside it. In California, the Department of Public Health submitted its readoption of the acute psychiatric hospital nurse-to-patient ratio emergency regulations to the Office of Administrative Law on November 9, with no decision posted by November 15, and amended Office of Health Care Affordability material change transaction rules took effect November 2, with a new flowchart on when a management services organization must file.

Primary stories

Medline bed recall: seven deaths and 35 serious injuries now reported; repair-and-replace customer guides coming

High priorityUpdatedRead article →

What changed

On November 13, 2026, FDA posted a Medline company announcement updating customers and patients on the repair and replace program for the recall of Medline Brand beds, rails, mattresses and accessories. Medline says that as of November 8, 2026 it has received reports related to seven deaths and 35 serious injuries associated with the fire hazard and entrapment issues, up from the two deaths and 16 serious injuries FDA's early alert reported as of October 20, 2026. Medline says it distributed the products in the United States and Canada between 2011 and 2026 to durable medical equipment providers, long-term care facilities and end users, and that it will soon begin distributing new repair and replace Customer Guides to patients and users. The continued-use instructions are unchanged: unplug the beds, plug in only while repositioning the patient, do not use extension cords, and have a second person assist whenever possible. To determine eligibility for repair, replacement or refund, customers contact the provider or distributor they bought or received the bed from, or Medline Recall Customer Service if they bought directly from Medline. On November 15, 2026, FDA's early alert page still showed content current as of October 29, 2026.

Background

FDA issued an Early Alert, listed October 29, 2026, after Medline told customers on October 14, 2026 that it is removing, discontinuing and exiting the market for all Medline Brand beds and associated components, including homecare, bariatric and long-term care beds, pendants, accessories, replacement parts and bed-containing order packages. Medline's October 24, 2026 update let covered beds, rails, mattresses and accessories remain in use under updated instructions until the bed is repaired or replaced; repair, replacement or refund may be available for certain products bought in the last five years.

Who this affects

Long-term care facilities, durable medical equipment providers, home-care patients and any hospital or other facility that has a Medline Brand bed, rail, mattress or accessory in use

Why it matters

The reported harm has risen from two deaths and 16 serious injuries (as of October 20) to seven deaths and 35 serious injuries (as of November 8), while the recalled beds may remain in use under precautions until each is repaired or replaced. Inference: every affected bed that is awaiting repair or replacement carries that exposure, and eligibility for a remedy now runs through the supplier the bed came from, so facilities that received beds through a distributor need that contact made.

Recommended action

  • Identify affected products and consult the complete current FDA and manufacturer instructions
  • Unplug beds except when repositioning; avoid extension cords; use a second person where possible (FDA-listed precautions)
  • Do not repair or modify beds except through the Medline-authorized process
  • Contact the provider or distributor the bed came from (or Medline Recall Customer Service for direct purchases) to determine repair, replacement or refund eligibility

Implementation playbook

  1. Confirm that every Medline Brand bed, rail, mattress and accessory still in service is on the recall inventory, by unit and location. Owner: Biomedical engineering and Facilities. Due: 2026-11-20.
  2. Re-brief nursing units on the unchanged precautions: beds unplugged except while repositioning the patient, no extension cords, a second person assisting whenever possible. Owner: Clinical operations. Due: 2026-11-20.
  3. For each bed received through a provider or distributor, contact that supplier to determine repair, replacement or refund eligibility and record the answer; for beds bought directly, contact Medline Recall Customer Service. Owner: Supply chain. Due: 2026-11-30.
  4. When the repair and replace Customer Guides arrive, schedule the work through the Medline-authorized process only. Owner: Biomedical engineering. Due: within 5 business days of receipt.
  5. Report any fire, burn or entrapment event involving these beds to MedWatch and to risk management. Owner: Risk management. Due: at each event.

Scope and timing

Authority status
Other (company recall announcement posted by FDA; FDA early alert)
Responsible owner
Facilities, Biomedical engineering, Clinical operations
Publication date
2026-11-13 (company announcement date and FDA publish date)
Other dates
2026-10-14 Medline removal notice; 2026-10-24 Medline update; 2026-10-29 FDA early alert; injury counts as of 2026-11-08

Not established

Medline's own recall page and the new Customer Guides were not opened.

Earlier article: November 8, 2026 edition →

Sources

FDA early alert: Arrow International removes catheters and guidewires with hydrophilic-coated spring wire guides over coating detachment and embolism risk

High priorityNew in this editionRead article →

What changed

The Food and Drug Administration (FDA) posted an early alert on November 10, 2026 about Arrow International, a subsidiary of Teleflex Incorporated, which has told customers to remove certain products that contain Spring Wire Guide components. Arrow sent the letter on November 5, 2026, telling customers to check inventory, stop using and distributing affected product, quarantine it and return it. Teleflex confirmed that the hydrophilic coating may swell unevenly when hydrated with saline, clump and potentially detach. Detached coating could release particles into the bloodstream and raise the risk of emboli. As of November 5, 2026, the firm had reported no serious injuries or deaths.

Background

An FDA early alert notifies the public of a potentially high-risk device issue while FDA reviews it. The affected Arrow coated guidewires help place catheters in blood vessels, and the recall also covers pressure-injectable catheters containing these guidewires that are used to deliver medicines and fluids and collect blood samples.

Who this affects

Hospitals and other facilities that stock or use Arrow hydrophilic-coated marked guidewires and Arrow pressure-injectable catheters and kits that contain them (vascular access teams, interventional radiology, critical care, supply chain)

Why it matters

Arrow recommends that affected guidewires and catheter kits be removed from where they are used or sold. Inference: removing them can interrupt vascular access supply until substitutes are in place. Inference: facilities that placed lines with affected products before the alert may want clinical review of any unexplained embolic events.

Recommended action

  • Search inventory and procedure carts against the full FDA affected-product list and quarantine matches
  • Return affected product to Teleflex/Arrow International and pass the notice to any facility you supplied
  • Arrange substitute guidewires and catheter kits with supply chain and the vascular access team
  • Report adverse events or quality problems to MedWatch

Implementation playbook

  1. Immediately retrieve the full affected-product list linked from the FDA early alert, search storerooms, procedure carts and kits for matches, stop using and distributing any match, and quarantine it. The Arrow letter, as FDA reports it, says to check inventory, cease use and distribution, and quarantine immediately. Owner: Supply chain with the Vascular access team. Due: immediately.
  2. Return the quarantined product to Arrow International and pass the notice to any facility the hospital supplies. Owner: Supply chain. Due: 2026-11-21.
  3. Confirm substitute guidewires and pressure-injectable catheter kits for vascular access, interventional radiology and critical care. Owner: Supply chain and Clinical engineering. Due: 2026-11-18.
  4. Ask clinical leaders whether unexplained embolic events after lines placed with affected product warrant review, and report any adverse event to MedWatch. Owner: Risk management. Due: 2026-12-15.

Scope and timing

Authority status
Other (FDA early alert)
Responsible owner
Supply chain, Clinical engineering, Vascular access and Interventional radiology, Risk management
Publication date
2026-11-10
Other dates
2026-11-05 Arrow International letter to affected customers; injury status as of 2026-11-05

Not established

The full list of affected product codes and lots linked from the FDA page was not retrieved.

Sources

FDA early alert: Intersurgical removes lots of 22mm Smoothbore breathing tubes and systems over connector disconnection and loss of ventilation risk

High priorityNew in this editionRead article →

What changed

The Food and Drug Administration (FDA) posted an early alert on November 10, 2026 about Intersurgical Inc., which has told customers to remove listed lots of its 22mm Smoothbore breathing tubes and systems. Intersurgical sent the letter on November 3, 2026, telling customers to stop using and quarantine stock with the affected product and lot numbers and return it. Testing of internal stock found some products were made with too little solvent to secure the soft connectors to the tube. A connector that disconnects during use could cause loss of ventilation or compromised ventilation. As of November 3, 2026, the firm had reported no serious injuries or deaths.

Background

An FDA early alert notifies the public of a potentially high-risk device issue while FDA reviews it. Intersurgical 22mm Smoothbore breathing tubes and systems connect patients to machines that help them breathe; the firm acted after reports from markets outside the U.S. of soft connectors disconnecting from the tube.

Who this affects

Hospitals using Intersurgical 22mm Smoothbore breathing tubes and heated-wire, bilevel and exhalation-valve breathing systems (respiratory therapy, critical care, anesthesia, supply chain)

Why it matters

FDA and Intersurgical say to stop using and quarantine affected lots, which include heated-wire and bilevel breathing systems. Inference: respiratory therapy needs replacement circuits on hand. A disconnection during use could cause loss of or compromised ventilation, which may cause the patient to desaturate until ventilation is manually re-initiated.

Recommended action

  • Check circuit stock against the reference and lot numbers on the FDA page and quarantine matches
  • Return affected product to Intersurgical and share the notice with all users in the facility
  • Confirm replacement circuits are available for ventilated and bilevel patients
  • Report adverse events or quality problems to MedWatch

Implementation playbook

  1. Immediately check breathing tube and circuit stock in respiratory therapy, critical care and anesthesia against the reference and lot numbers on the FDA page, stop using any match, quarantine any stock with the affected product and lot numbers, and share the notice with every unit that sets up ventilator, bilevel or heated-wire breathing circuits. The Intersurgical letter, as FDA reports it, says to discontinue use and quarantine immediately. Owner: Respiratory therapy and Supply chain. Due: immediately.
  2. Return the quarantined lots to Intersurgical. Owner: Supply chain. Due: 2026-11-21.
  3. Confirm replacement circuits are stocked for ventilated and bilevel patients. Owner: Respiratory therapy. Due: 2026-11-18.
  4. Report any connector disconnection or loss of ventilation to MedWatch and to risk management. Owner: Risk management. Due: at each event.

Scope and timing

Authority status
Other (FDA early alert)
Responsible owner
Respiratory therapy, Supply chain, Clinical engineering, Critical care
Publication date
2026-11-10
Other dates
2026-11-03 Intersurgical letter to affected customers; injury status as of 2026-11-03

Sources

CDPH submits readoption of acute psychiatric hospital nurse-to-patient ratio emergency regulations to OAL

Medium priorityUpdatedRead article →

What changed

The Office of Administrative Law (OAL) lists a California Department of Public Health (CDPH) emergency action titled Acute Psychiatric Hospitals, amending Title 22 sections that OAL lists as 71213 and 71215 (CDPH's October 30, 2026 All Facilities Letter names sections 71213.1 and 71215.1, and this difference was not resolved), as submitted on November 9, 2026 under OAL file 2026-1109-02EEFP. OAL's list covers proposed emergency actions that have been submitted and are currently under review. OAL must allow five calendar days for public comments after posting notice of an emergency filing, unless the emergency situation clearly poses such an immediate, serious harm that delaying action to allow public comment would be inconsistent with the public interest. On November 15, 2026, OAL had not posted a decision, and CDPH's rulemaking page for DPH-19-001E still showed only the original emergency history.

Background

The emergency regulations under CDPH file DPH-19-001E amend Title 22 sections that CDPH's rulemaking page lists as 71213 and 71215 for acute psychiatric hospitals; CDPH's October 30, 2026 All Facilities Letter names the readoption sections as 71213.1 and 71215.1, and the section numbers were not checked against the regulatory text. CDPH filed them with OAL on May 22, 2026, and they took effect June 1, 2026. CDPH's rulemaking page lists readoption documents: a Notice of Emergency Readopt, a Finding of Emergency and proposed text.

Who this affects

Acute psychiatric hospitals licensed in California, and their nursing leadership and staffing functions.

Why it matters

If OAL approves the readoption, the emergency staffing rules that the filing amends continue past their current term; if it does not, the emergency text would lapse when its current term ends. CDPH's notice of readoption says the readopted regulations would be in effect November 28, 2026. Inference: the current emergency term runs until about then.

Recommended action

  • Watch OAL's decision on file 2026-1109-02EEFP and confirm the readopted text matches the staffing rules now in use.
  • Keep current nurse-to-patient ratio practices at licensed acute psychiatric hospitals aligned with the emergency regulations now in effect under CDPH file DPH-19-001E while the readoption is under review.

Implementation playbook

  1. Check OAL's decision on file 2026-1109-02EEFP and record the outcome. Owner: Compliance. Due: 2026-11-30.
  2. When OAL decides, confirm the section numbers against the readopted regulatory text (OAL lists 71213 and 71215, and CDPH's letter names 71213.1 and 71215.1), then compare that text with current staffing practice at the affected licensed acute psychiatric hospitals. Owner: Nursing administration. Due: within 10 business days of the decision.

Scope and timing

Authority status
Proposed
Responsible owner
Nursing administration; Compliance
Other dates
2026-11-09: submitted to the Office of Administrative Law (OAL), file 2026-1109-02EEFP, per OAL's Emergency Regulations Under Review list

Not established

OAL's decision on the readoption had not been posted when checked. The Notice of Emergency Readopt and Finding of Emergency PDFs were not opened.

Earlier article: November 8, 2026 edition →

Sources

Federal IDR dispute web forms move into the IDR Gateway; disputes cannot start outside it after January 15, 2027

Medium priorityNew in this editionRead article →

What changed

CMS's About Independent Dispute Resolution page, last modified November 13, 2026, says that as of November 13, 2026, users of the independent dispute resolution (IDR) Gateway can submit the Notice of IDR Initiation, IDR Entity Selection Response and Notice of Offer web forms in the Gateway. The single-use web forms will no longer be available outside the IDR Gateway after January 15, 2027, and parties will not be able to start a dispute outside the Gateway after that date. Organizations and individuals that process disputes, represent parties or submit IDR web forms must sign up to continue managing disputes in the IDR Gateway.

Background

The No Surprises Act created protections against out-of-network balance billing and established independent dispute resolution, managed by the Departments of Health and Human Services, Labor and the Treasury, which providers, facilities and health plans can use to determine payment rates for certain out-of-network charges.

Who this affects

Hospitals, facilities and providers (and their representatives) that start or manage federal independent dispute resolution disputes with health plans

Why it matters

After January 15, 2027, a facility or provider that has not signed up for the IDR Gateway cannot start a federal dispute, and a dispute must be started within 4 business days after open negotiation ends unless the Departments extend that time. Inference: that window leaves little time to set up access when a dispute is due. Inference: revenue-cycle teams and any outside dispute vendors need Gateway accounts in place before that date.

Required actions

  • After January 15, 2027, start federal IDR disputes only through the IDR Gateway (CMS page)

Recommended action

  • Sign up revenue-cycle staff and any dispute representatives for the IDR Gateway before January 15, 2027
  • Move dispute initiation, entity selection and offer submissions to the Gateway web forms now

Implementation playbook

  1. Sign up revenue-cycle staff who start or manage federal IDR disputes, and any outside dispute representative, for the IDR Gateway. Owner: Revenue Cycle. Due: 2026-12-15.
  2. Move Notice of IDR Initiation, IDR Entity Selection Response and Notice of Offer submissions to the Gateway web forms and update dispute procedures. Owner: Revenue Cycle and Managed Care Contracting. Due: 2027-01-08, ahead of the January 15, 2027 cutoff.
  3. Confirm that dispute vendors will submit through the Gateway after January 15, 2027. Owner: Managed Care Contracting. Due: 2026-12-31.

Scope and timing

Authority status
Announced
Responsible owner
Revenue Cycle; Managed Care Contracting
Implementation date
2026-11-13 (web forms available in the IDR Gateway)
Other dates
2027-01-15: single-use web forms outside the IDR Gateway end after this date; no dispute can be started outside the Gateway after it; CMS page last modified 2026-11-13

Not established

The IDR Gateway page and the Notices page were not opened, and the date the web-form notice was first posted is not established.

Sources

CMS publishes CARE proposed rule (CMS-3484-P) in the Federal Register; comments assured consideration if received by January 11, 2027

Medium priorityUpdatedRead article →

What changed

The Federal Register published the Cutting Administrative Requirements for Excellence in Patient Care (CARE) proposed rule on November 10, 2026 at 91 FR 72634 (FR Doc. 2026-22812, docket CMS-3484-P). Its Dates section states that, to be assured consideration, comments must be received by January 11, 2027. The Federal Register record, read on November 15, 2026, lists no corrections. Nothing in the proposal is final; CMS's November 5, 2026 fact sheet describes the obstetric requirements it would remove as otherwise effective January 1, 2027; they would be removed only if CMS finalizes the proposal.

Background

On November 5, 2026, the Centers for Medicare & Medicaid Services (CMS) issued the Cutting Administrative Requirements for Excellence in Patient Care (CARE) proposed rule, which would revise Conditions of Participation after a review of those for all 21 provider and supplier types. For hospitals and critical access hospitals it would remove staff training requirements for emergency services readiness and obstetric care and the obstetric-specific Quality Assessment and Performance Improvement (QAPI) requirements otherwise effective January 1, 2027, and it would adopt the 2024 National Fire Protection Association (NFPA) Life Safety Code and Health Care Facilities Code. The public-inspection copy reported in the November 8 edition left the comment date in brackets.

Who this affects

Hospitals, critical access hospitals (CAHs), rural emergency hospitals, long-term care facilities, intermediate care facilities for individuals with intellectual disabilities, hospice inpatient facilities and other providers subject to CoPs; states (Medicaid institutional payment transparency reporting).

Why it matters

Inference: this is a proposal, so the obstetric CoP requirements otherwise effective January 1, 2027 remain on schedule unless CMS finalizes the removal; hospitals preparing OB training and QAPI programs should keep preparing while tracking the rule. Inference: facilities would need a Life Safety Code gap review against the 2024 edition if the rule is finalized.

Recommended action

  • Decide whether to comment; comments received by January 11, 2027 are assured consideration.
  • Keep January 1, 2027 OB CoP readiness work on track until a final rule says otherwise.
  • Facilities and engineering: begin a gap review of the 2024 NFPA 101 and 99 editions.

Implementation playbook

  1. Decide whether to comment on CMS-3484-P and assign the drafting. Owner: Regulatory Compliance. Due: 2026-12-11.
  2. Submit any comment through the docket. Owner: Regulatory Compliance. Due: 2027-01-08, ahead of the January 11, 2027 assured-consideration date.
  3. Keep obstetric training and quality program work for the January 1, 2027 requirements on schedule until a final rule says otherwise. Owner: Women's services and Nursing. Due: 2026-12-31.
  4. Start a gap review of facilities against the 2024 NFPA 101 and 99 editions named in the proposal. Owner: Facilities. Due: 2027-03-31.

Scope and timing

Authority status
Proposed
Responsible owner
Regulatory Compliance; Nursing/Women's services; Facilities
Publication date
2026-11-10
Other dates
2027-01-11: comments assured consideration if received by this date (Federal Register Dates section); placed on public inspection 2026-11-05; CMS fact sheet dated 2026-11-05; the obstetric QAPI and training requirements the rule would remove are otherwise effective 2027-01-01

Not established

The critical access hospital distance-exemption and the certified registered nurse anesthetist comment solicitation were not reviewed for this entry.

Earlier article: November 8, 2026 edition →

Sources

FDA lists a Class I recall of four lots of the Edwards Commander M mitral valve delivery system over a manufacturing issue that may cause balloon rupture

Medium priorityNew in this editionRead article →

What changed

The U.S. Food and Drug Administration's (FDA) Enforcement Report for the week of November 11, 2026 lists a Class I recall by Edwards Lifesciences, LLC of the Edwards Commander M Delivery System, model 9880CM29A, a delivery system for a percutaneously delivered mitral valve prosthesis. The recall covers lot numbers 67718561, 67804014, 67887043 and 67887044. The reason given is a manufacturing issue which may result in cardiovascular balloon rupturing.

Who this affects

Hospitals with structural heart or cardiac catheterization programs that stock the Edwards Commander M Delivery System, model 9880CM29A, and their supply chain and risk management teams.

Why it matters

Inference: hospitals holding the listed lots should set them aside until the firm's instructions are confirmed. The firm's customer notice and its instructions were not retrieved, so the steps below are recommended practice, not the firm's stated instructions.

Recommended action

  • Search cath lab and structural heart inventory for model 9880CM29A, lots 67718561, 67804014, 67887043 and 67887044, and quarantine any found.
  • Confirm with Edwards Lifesciences whether a customer notice was received and follow its return or replacement instructions, documenting the response.

Implementation playbook

  1. Search cath lab and structural heart inventory for model 9880CM29A, lots 67718561, 67804014, 67887043 and 67887044, and quarantine any found. Owner: Cardiovascular Services and Supply Chain. Due: 2026-11-18.
  2. Ask Edwards Lifesciences whether a customer notice was sent, follow its return or replacement instructions, and document the response. Owner: Supply Chain. Due: 2026-11-25.
  3. Review any balloon rupture during a procedure with these lots and report it to MedWatch. Owner: Risk Management. Due: 2026-11-30.

Scope and timing

Authority status
Recall classification
Responsible owner
Cardiovascular Services; Supply Chain; Risk Management
Other dates
2026-11-11: FDA Enforcement Report for the week of November 11, 2026; 2026-11-02: posted internet date of the record

Not established

The firm's customer notice, recall initiation date, quantity and distribution were not retrieved. Whether FDA posted a separate recall notice page was not checked.

Sources

Continuing obligations

Eugia recalls one lot of vancomycin injection to the hospital level for glass particulate

High priorityConditional reminderRead article →

What this is

Eugia US LLC announced on November 6, 2026 a voluntary nationwide recall, to the hospital/healthcare facility/user level, of one lot (3VM26026A) of Vancomycin Hydrochloride for Injection USP (United States Pharmacopeia) 1.25g/Vial-30mL because a glass particle was found inside a vial; FDA posted the announcement on November 9, 2026. The lot shipped to wholesalers nationwide from September 2 through September 15, 2026, and holders are told to discontinue use and quarantine it immediately.

Current status

On November 15, 2026, FDA's posting of the Eugia announcement still showed content current as of November 9, 2026, and FDA's drug enforcement records (openFDA) returned no Eugia record with a report date from October 1 through November 15, 2026, so this check did not establish an FDA recall classification. FDA's MedWatch feed listed no later item on the recall.

Who this affects

Hospitals, health-system pharmacies and infusion sites holding Eugia vancomycin hydrochloride for injection 1.25 g vials, lot 3VM26026A.

Why it matters

The company says there is a reasonable probability that use of product containing glass particulates can cause serious adverse health consequences such as blockage and clotting in blood vessels, with greater susceptibility in neonates, infants and patients with compromised organ function. Inference: any unit of lot 3VM26026A still in a pharmacy, satellite or automated cabinet remains a patient-safety exposure until it is quarantined and returned.

Required actions

  • None stated as a legal requirement; the company announcement directs holders of the lot to discontinue use and quarantine immediately (2026-11-06 announcement).

Recommended action

  • Search all pharmacy locations and cabinets for lot 3VM26026A and quarantine
  • Inform clinicians of the recall as the announcement asks
  • Document the recall response in the drug recall log

Scope and timing

Authority status
Other (company-initiated voluntary recall announcement posted by FDA)
Responsible owner
Pharmacy
Publication date
2026-11-09 (FDA publish date)
Other dates
2026-11-06 company announcement date; lot shipped 2026-09-02 to 2026-09-15

Not established

FDA recall classification not established.

Earlier article: November 8, 2026 edition →

Sources

OHCA first-year provisional NOLA (labor-cost adjustment) requests still due November 16, 2026

High priorityConditional reminderRead article →

What this is

California's Office of Health Care Affordability (OHCA) enforces health care spending targets set by its Health Care Affordability Board, and the law lets the Board adjust targets when non-supervisory organized labor costs are expected to grow faster than the target, through a Non-Supervisory Organized Labor Adjustment (NOLA). For the first year, OHCA must receive all requests for a provisional NOLA by November 16, 2026 (by the end of October in future years). NOLAs apply to providers and fully integrated delivery systems, not health plans; a labor union may initiate a request but the regulated entity must attest, and all NOLAs are provisional until confirmed with actual expenditure data.

Current status

On November 15, 2026, the Office of Health Care Affordability (OHCA) Slow Spending Growth page still stated that, for the first year, OHCA must receive all requests for a provisional Non-Supervisory Organized Labor Adjustment (NOLA) by November 16, 2026, and that requests can be submitted at the NOLA Portal. The portal itself was not opened.

Who this affects

Providers and fully integrated delivery systems subject to OHCA spending targets (not health plans), and labor unions initiating requests on their behalf

Why it matters

Inference: a hospital or system expecting non-supervisory organized labor cost growth above the target can have a provisional adjustment considered only if its request reaches OHCA by November 16, 2026. Without one, OHCA's page says an entity that misses the spending target is sent a notice of exceeding it and potential enforcement action, and then has 45 days to show that growth in non-supervisory organized labor costs caused all or part of the excess.

Required actions

  • A provider seeking a first-year provisional NOLA must have its request received by OHCA by 2026-11-16 (NOLA portal).

Recommended action

  • Decide whether to file; if a union initiates, prepare for the attestation step.
  • Retain the projections and labor-agreement support, since NOLAs are provisional pending actual data.

Scope and timing

Authority status
Operative duty
Responsible owner
Finance; Labor Relations; Legal; Compliance
Compliance date
2026-11-16
Other dates
Page last modified 2026-11-04 according to the page records of the Department of Health Care Access and Information (HCAI) website (what changed not established); future years due end of October

Not established

The NOLA portal was not opened.

Earlier article: November 8, 2026 edition →

Sources

HemosIL AcuStar HIT-IgG(PF4-H) lot recall: destroy listed lots and document on the response form

High priorityConditional reminderRead article →

What this is

FDA identified as the most serious type of recall the removal of four lots of an assay that, with other laboratory and clinical findings, aids in determining the risk for heparin-induced thrombocytopenia (HIT): HemosIL AcuStar HIT-IgG(PF4-H), from Instrumentation Laboratories (Werfen). Werfen found a performance issue in lots B40005, B40006, B38062 and B38063 that may cause a negative bias, so sample results could be incorrectly reported below the assay cut-off (1.00 U/mL) and be interpreted as HIT IgG antibody negative. The earlier article reported FDA's listing of the confirmed recall on October 30, 2026, and FDA says a supply interruption is expected.

Current status

On November 15, 2026, FDA's recall page still showed content current as of October 30, 2026 with the lot-check, destruction and response-form instructions, FDA's list of recalls and early alerts still showed the recall dated October 30, 2026 with status Recall Confirmed, and FDA's MedWatch feed listed no later item on it.

Who this affects

Hospital laboratories running HemosIL AcuStar HIT-IgG(PF4-H)

Why it matters

A result from an affected lot incorrectly reported below the cut-off may delay recognition of heparin-induced thrombocytopenia (HIT), and FDA says that in patients with HIT, continued exposure to heparin may increase the risk of thrombotic complications. Laboratories need an alternative HIT antibody method because a supply interruption is expected.

Recommended action

  • Check inventory for lots B40005, B40006, B38062, B38063 and destroy remaining product under facility procedures (FDA)
  • Document destruction on the Urgent Mandatory Response Tracking Form (FDA)
  • Identify an alternative HIT antibody testing method

Scope and timing

Authority status
Other (FDA recall)
Responsible owner
Laboratory, Hematology, Patient safety
Publication date
2026-10-30

Not established

Manufacturer letter not reviewed.

Earlier article: November 8, 2026 edition →

Sources

FDA early alert: ButterflyBVM bag-valve-mask resuscitators, removal of lots 000109 to 000117 and pre-use test for others

High priorityConditional reminderRead article →

What this is

The Food and Drug Administration (FDA) issued an Early Alert on November 3, 2026 about Compact Medical's "Urgent Medical Device Recall" for certain lots of ButterflyBVM single-use bag-valve-mask resuscitators: lots 000109 through 000117 are to be removed, and listed earlier lots get a correction, to perform the Pre-Use Test before every use and not use any unit that fails. A hole can form in the bellows, which FDA says can cause inadequate ventilation and hypoxia; the firm sent letters on September 26 and October 7, 2026.

Current status

On November 15, 2026, the FDA Early Alert page showed content current as of November 3, 2026, the date it was issued, and FDA's list of medical device recalls and early alerts showed the item in a row dated 11/03/2026 with the status "Early Alert – FDA collecting information".

Who this affects

Hospitals, emergency medical services and any care area stocking ButterflyBVM single-use bag-valve-mask resuscitators (crash carts, code kits, transport).

Why it matters

If a hole develops in the bellows, tidal volume can leak from the device instead of reaching the patient; FDA says the leak can cause inadequate ventilation and hypoxia and, if not corrected, could result in serious injury or death. Clinical engineering, supply chain and respiratory therapy need to locate affected lots in every location (crash carts, kits, storage), replace removal lots only after a replacement bag-valve-mask (BVM) is in place, and add the pre-use test for correction lots. Inference: code-cart check lists may need a temporary step.

Required actions

  • None stated as a legal requirement; the firm's recommended actions are summarized on the FDA page (letters dated 2026-09-26 and 2026-10-07).

Recommended action

  • Inventory all BVMs by lot at every location
  • Remove lots 000109 to 000117 once replacements are in place
  • Add the Pre-Use Test for correction lots and brief staff
  • Keep backup BVMs available

Scope and timing

Authority status
Other (Early Alert from FDA's Center for Devices and Radiological Health (CDRH) of a firm-initiated removal and correction)
Responsible owner
Clinical Engineering; Supply Chain; Respiratory Therapy
Publication date
2026-11-03
Other dates
Firm letters 2026-09-26 and 2026-10-07; injury status as of 2026-11-02

Not established

The firm's letters were not retained. The FDA page states no recall classification.

Earlier article: November 8, 2026 edition →

Sources

StatStrip Gen 2.0 glucose meter Class I correction: interim safeguards until the software update

High priorityConditional reminderRead article →

What this is

FDA identified Nova Biomedical's correction of its StatStrip Glucose Hospital Meter System as the most serious type of recall (Class I): on the Gen 2.0 model only, prior patient or quality-control information may remain on the meter screen when a barcode is scanned and, if accepted, assign a glucose result to the wrong patient. FDA issued its communication on October 20, 2026 and updated it on October 30 to clarify the recommended actions. Nova intends to roll out a software update in November 2026 in a phased manner; until then users follow updated instructions or, if an alternative meter is available, stop using the affected meter.

Current status

On November 15, 2026, the FDA page showed content current as of October 30, 2026, the same date the November 8 edition reported, and still told users to follow the updated instructions while awaiting a software update; it does not report the update as available. FDA's recall list shows the item in a row dated 10/30/2026.

Who this affects

Hospitals using Nova Biomedical StatStrip Gen 2.0 glucose hospital meters

Why it matters

A glucose result assigned to the wrong patient can lead clinicians to act on another patient's value; FDA's page says this could mean delayed treatment, unnecessary treatment (including inappropriate insulin administration) or failure to treat the intended patient, and that critically ill patients and infants are at greater risk. Until the software update reaches a hospital's meters, units without an alternative meter depend on the manufacturer's mitigation steps, including staff checking the patient identification after every barcode scan and again on the result screen.

Recommended action

  • If an alternative meter is available, stop using the affected StatStrip meter until it is updated (FDA recommendation)
  • Otherwise follow the manufacturer's interim safeguards, including patient identification checks
  • Identify affected models, review FDA's current instructions and confirm mitigation and software-update plans

Scope and timing

Authority status
Other (FDA Class I recall correction communication)
Responsible owner
Clinical operations, Laboratory (point-of-care testing), Biomedical engineering, Patient safety
Publication date
2026-10-20
Other dates
2026-10-30 FDA update; the FDA page says Nova intends to roll out the software update in November 2026, in phases (no exact date)

Not established

Manufacturer letters were not retained. Whether Nova has begun the November software rollout at any site is not established.

Earlier article: November 8, 2026 edition →

Sources

B. Braun Dialog+ bloodline early alert: three Streamline Bloodline Set lots removed over connector detachment risk

High priorityConditional reminderRead article →

What this is

FDA issued an Early Alert on a potentially high-risk device issue: B. Braun Medical Inc. has recommended to customers that lots A2600099, A2600128 and A2600136 of its Streamline Bloodline Set for Dialog+, model SL-2010M2096, be removed from where they are used or sold. B. Braun stated that a required solvent application step during assembly was not performed, leaving the dialyzer connector inadequately bonded, so the bloodline connector may detach or leak during priming or dialysis treatment, potentially leading to blood loss, clotting and occlusion of the extracorporeal circuit, or air entering the blood circuit. B. Braun sent customers a letter on October 20, 2026, and the earlier article reported FDA's device-safety listing of the alert on October 27, 2026.

Current status

On November 15, 2026, the FDA page showed content current as of November 2, 2026, the same date the November 8 edition reported, and FDA's list of medical device recalls and early alerts showed the alert in a row dated 11/02/2026 with the status "Early Alert – FDA collecting information".

Who this affects

Dialysis units using Streamline Bloodline Set for Dialog+ model SL-2010M2096

Why it matters

A set from an affected lot can come apart or leak during treatment; FDA's page says hemodialysis patients are medically fragile, that extracorporeal blood loss may require clinical assessment, corrective treatment, professional medical intervention or hospitalization, and that in severe cases significant blood loss could be life-threatening. Inference: dialysis units need enough unaffected sets to replace any stock they quarantine and return.

Recommended action

  • Inform all users; identify and quarantine affected devices (FDA)
  • Determine inventory, cease use, quarantine and return affected product (manufacturer letter as described by FDA)

Scope and timing

Authority status
Other (FDA early alert)
Responsible owner
Dialysis services, Supply chain
Publication date
2026-10-27 (FDA listing date as the earlier article states; the FDA list read on November 10, 2026 shows 11/02/2026)
Other dates
2026-10-20 manufacturer letter; FDA page content current 2026-11-02

Not established

What FDA changed on the page on November 2 is not established. B. Braun's letter to customers was not retained.

Earlier article: November 8, 2026 edition →

Sources

Transparency in Coverage final rule: phased machine-readable file and phone-disclosure duties still ahead

High priorityConditional reminderRead article →

What this is

The Transparency in Coverage final rule (FR Doc. 2026-20447, 91 FR 63748), published in the Federal Register on October 6, 2026 and effective December 7, 2026, sets new disclosure duties for non-grandfathered group health plans and health insurance issuers: in-network rate files for each provider network, out-of-network allowed-amount files for each health insurance market, new contextual files, a website footer link labeled Price Transparency or Transparency in Coverage, attestations in the files, and cost-sharing information available by phone. The duties phase in for plan years (policy years in the individual market) beginning on or after January 1, 2027 (the amended cost-sharing disclosures, including the phone method), on March 6, 2027 (the rate and allowed-amount file changes and attestations) and on September 6, 2027 (the contextual files and footer), with the first utilization file due July 1, 2028; until each date the prior rules continue to apply.

Current status

On November 15, 2026, the Federal Register application programming interface (API) record for the rule still gave an effective date of December 7, 2026 and listed no corrections, and a Federal Register search for "Transparency in Coverage" in documents published November 8 to 14, 2026 returned none (a bounded search). The Centers for Medicare & Medicaid Services (CMS) price-transparency schema repository on GitHub showed no release after version 2.0.0, published October 1, 2025, and its default branch showed no commits since October 1, 2026 (other branches were not checked). Prior-rule compliance continues until each applicability date.

Who this affects

Non-grandfathered group health plans and health insurance issuers offering non-grandfathered group or individual coverage. Inference: this reaches a hospital or health system as sponsor of its own employee group health plan (self-insured plans stay liable when a third-party administrator (TPA) fails to deliver; insured plans can shift liability to the issuer by written agreement) and any health plan or issuer the system owns. Grandfathered plans and coverage are not otherwise subject to these rules; the rule's summary says that meeting the phone requirement also satisfies section 114 of the No Surprises Act, including for grandfathered plans and coverage (the earlier article described this as the phone-estimate provision reaching grandfathered coverage). Provider contracting and revenue-cycle teams are affected as users of payer rate files (inference).

Why it matters

A hospital or health system that sponsors a non-grandfathered group health plan carries these duties: the amended cost-sharing disclosures, including the phone method, for plan years beginning on or after January 1, 2027, the rate and allowed-amount file changes and attestations from March 6, 2027, and the contextual files and footer from September 6, 2027. A self-insured plan remains liable if its third-party administrator fails to provide the information, while under a written agreement the issuer of an insured plan, not the plan, is in violation if the issuer fails.

Required actions

  • Until each applicability date, continue to comply with the prior Transparency in Coverage rules (2715A3(c)(1)(i) and parallel sections).
  • For plan years (policy years in the individual market) beginning on or after 2027-01-01: make cost-sharing information available by phone through the number on the ID card, accurate and provided at the time of the request (2715A2(b)(2)(iii), (c)(1)).
  • From 2027-03-06: in-network rate files per provider network; exclusion of provider-rate combinations unlikely to be reimbursed given specialty; market-level out-of-network allowed-amount files omitting items with fewer than 11 claims; and, in the specified machine-readable files, an attestation made to the best of the plan's or issuer's knowledge and belief as of the date in the file, naming the plan's or issuer's CEO, president or a senior official designated to oversee the encoding of the data, or, under a qualifying written agreement, the other party's CEO, president or such a designated senior official (2715A3(b)(1), (c)(1)(ii)).
  • Post and update in-network rate and allowed-amount files quarterly on the first day of each calendar-year quarter after the March 6, 2027 applicability date (April 1, 2027 per the earlier article); prescription-drug file updated monthly (2715A3(b)(4)(i)-(ii)).
  • Provisions applicable from 2027-09-06: the taxonomy file, the root-folder plain-text file with source URL, direct link and a monitored point of contact, and a footer link labeled Price Transparency or Transparency in Coverage. The taxonomy and text files first post on the first day of the first calendar-year quarter after September 6, 2027 (October 1, 2027 per the earlier article); after that the taxonomy file is posted on the first day of each calendar-year quarter, and it must still be posted, though it need not be updated, when no taxonomy change affects the information required in the in-network rate file from one quarter to the next; the text file is updated as soon as practicable and not later than 7 calendar days after a change; the footer link goes on the home page and on other pages that feature a footer (2715A3(b)(2), (b)(3)(iii), (b)(4)(iii)-(v), (c)(1)(ii)).
  • Utilization file: first posting July 1, 2028, and annually thereafter (2715A3(b)(4)(iii)). It is not due on September 6, 2027.

Recommended action

  • Inventory affected plan products and vendors, preserve the three distinct implementation phases, and test accurate consumer estimates against current data (earlier article).
  • Map vendor deliverables and consumer-estimate accuracy to each separate phase (earlier article, forward horizon).
  • Confirm written agreements with TPAs and issuers cover each new file, the attestation and the phone method (inference from the rule's contracting provisions).
  • Do not treat every new file as due in September 2027; keep the April 1, 2027, October 1, 2027 and July 1, 2028 posting dates separate (earlier article).

Scope and timing

Authority status
Final
Responsible owner
Proposed: Benefits (plan sponsor/plan administrator) with Legal; Compliance for attestation governance; Managed Care Contracting and Revenue Cycle as data users. The prior coverage did not specify an owner.
Publication date
2026-10-06
Effective date
2026-12-07
Compliance date
2027-03-06 (in-network rate and out-of-network allowed-amount file changes and attestations; 26 CFR 54.9815-2715A3(c)(1)(ii) and parallel Department of Labor (DOL) and HHS sections); 2027-09-06 (contextual files, website footer and their timing rules)
Implementation date
2027-01-01 (amended consumer cost-sharing disclosure provisions, including the phone method, apply for plan years beginning on or after this date; 2715A2(c)(1))
Other dates
2027-04-01 first quarterly posting of rate and allowed-amount files (first calendar-year quarter after March 6, 2027, as the earlier article states); 2027-10-01 first posting of taxonomy and text files (first calendar-year quarter after September 6, 2027, as the earlier article states); 2028-07-01 first utilization file posting, annually thereafter

Not established

Technical implementation guidance on CMS web pages was not checked. The April 1, 2027 and October 1, 2027 first posting dates come from the earlier article's reading of the quarterly rule, not dates printed in the regulatory text. The owner named above is a proposal.

Earlier article: November 8, 2026 edition →

Sources

Continuing items (97)
ItemPriorityDates still aheadWhat stands behind this rowEarlier article
CDPH AFL 26-33 updates hospital respiratory-virus surge guidance for 2026-2027 and supersedes AFL 23-30Medium priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
Labor Department finalizes PBM fee-disclosure rule for large self-insured ERISA health plansMedium priorityJanuary 4, 2027 (effective)
July 1, 2027 (implementation: Applicable to plan years beginning on or after)
An official source was re-read on November 15, 2026November 8, 2026 edition
Cardinal Health Presource kits with recalled BD Alaris infusion setsMedium priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
OIG adds FAQMedium priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
CDPH permanent hospice agency regulationsMedium priorityDecember 14, 2026 (comment deadline)
December 15, 2026: public hearing, 10:00 a.m. to 12:00 p.m. Pacific
An official source was re-read on November 15, 2026November 4, 2026 edition
FTC healthcare marketing warning-letter templateMedium priorityNone recordedPartly checked; current status not establishedNovember 4, 2026 edition
HHS maternity CPT enforcement discretionMedium priorityJanuary 1, 2027 (operative: enforcement discretion begins)
December 31, 2027: discretion ends
An official source was re-read on November 15, 2026November 4, 2026 edition
HTI-5 final ruleMedium priorityDecember 28, 2026 (effective)
January 1, 2027: effective date for amendatory instructions 7, 10 and 12
An official source was re-read on November 15, 2026November 4, 2026 edition
OIG patient-engagement safe-harbor cap of $646 applies for calendar year 2027Medium priorityJanuary 1, 2027 (effective: calendar year the cap applies)An official source was re-read on November 15, 2026November 4, 2026 edition
Cal/OSHA egregious and enterprise-wide violations proposalMedium priorityNovember 30, 2026 (comment deadline: written comments must be received by this date, or may be submitted at the public hearing on December 3, 2026)
December 3, 2026: public hearing, 10:00 a.m., Oakland and Zoom
An official source was re-read on November 15, 2026November 4, 2026 edition
DOJ Fraud Division and HHS-OIG coordinate a single qualifying criminal health care self-disclosureMedium priorityNone recordedAn official source was re-read on November 15, 2026October 18, 2026 edition
DEA notice of intent on 7-hydroxymitragynine and mitragynine pseudoindoxylMedium priorityNone recordedAn official source was re-read on November 15, 2026October 18, 2026 edition
CDPH AFL 26-29Medium priorityNone recordedAn official source was re-read on November 15, 2026October 18, 2026 edition
California home health licensure moratoriumMedium priorityMarch 31, 2027 (compliance)An official source was re-read on November 15, 2026October 11, 2026 edition
OCR September 3 letter on antisemitic discrimination in HHS-funded programsMedium priorityNone recordedFrom the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 173 Medi-Cal enrollment integrity controlsMedium priorityNone recordedFrom the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 1405 AI auditor registrationMedium priorityJanuary 1, 2029 (compliance: from this date a person may not offer, sell or conduct a covered AI audit without registration) (as the earlier article reported; not re-verified)
January 1, 2029: Government Operations Agency to establish the AI Auditor Registry by 2029-01-01 (as the earlier article reported; not re-verified)
From the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 2311 health care district physician-employment exceptionMedium priorityJanuary 1, 2027 (effective)
January 1, 2037: employment authority ends 2037-01-01.
Partly checked; current status not establishedOctober 11, 2026 edition
AB 2562 suicide-prevention plans for covered alcohol and drug programsMedium priorityJanuary 1, 2027 (effective)
January 1, 2031: DHCS must adopt regulations by 2031-01-01 (department rulemaking deadline, not a licensee filing date).
Partly checked; current status not establishedOctober 11, 2026 edition
DOJ September 18 Justice Manual revisions on sub-regulatory guidance and qui tam dismissalMedium priorityNone recordedAn official source was re-read on November 15, 2026October 11, 2026 edition
AB 2613 electronic provider-termination notices for health plansMedium priorityJanuary 1, 2027 (effective)Partly checked; current status not establishedOctober 11, 2026 edition
AB 1983 repayable continuing-care contract sequencing and interest rulesMedium priorityJanuary 1, 2027 (effective: interest rule applies to sequential contracts entered into on or after this date) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 1447 syndromic-surveillance reportingMedium priorityDecember 31, 2028 (compliance: or within one year of official department notification, whichever is sooner) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 934 updated conversion-therapy prohibition for patients under 18Medium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 1114 SOGI and intersex data disclosure limits for enumerated state agenciesMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)
January 1, 2028: DSS external-disclosure restrictions no later than 2028-01-01 (as the earlier article reported; not re-verified)
From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 1302 nursing medication-order and credentialing changesMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)
January 1, 2029 (compliance: continuing-education proof at renewal from this date) (as the earlier article reported; not re-verified)
January 1, 2028: BRN must identify qualifying states by 2028-01-01 (Board duty) (as the earlier article reported; not re-verified)
From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 923 CCPA deletion of third-party personal informationMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 1798 genetic-information limits in life and disability underwritingMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 503 clinical decision-support bias dutiesMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 1323 mandatory visitor procedures and immigration-access noticeMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)
January 1, 2030: (mandatory procedure and notice terms apply until this date, when replacement provisions take over) (as the earlier article reported; not re-verified)
From the earlier article; not re-verified for this editionOctober 11, 2026 edition
SB 1088 POLST updatesMedium priorityJanuary 1, 2027 (effective: forms printed after this date must contain the specified representative acknowledgment) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 1331 and AB 1883 workplace bathroom-surveillance and emotional-AI limitsMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 1609 customer-service chatbot rulesMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 2009 plasma-center personnel-change and donor-identification rulesMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 2405 and AB 2318 crisis-transport destination and medical-access rulesMedium priorityJanuary 1, 2027 (effective) (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
CLIA virtual-access and digital cytology proficiency-testing proposalMedium priorityDecember 7, 2026: comments must be received by this date to be assured considerationAn official source was re-read on November 15, 2026October 11, 2026 edition
HRSA living-donor reimbursement guidelines without recipient-income testMedium priorityNone recordedAn official source was re-read on November 15, 2026October 11, 2026 edition
OIG updated its Health Care Fraud Self-Disclosure ProtocolMedium priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
FDA classifies Abiomed Automated Impella Controller removal as Class IMedium priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
Baxter TruSystem surgical tablesMedium priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
Off-campus provider-based departments need a separate NPI and a provider-based attestation (by December 31, 2027 for departments furnishing services on or before January 1, 2028), or lose OPPS paymentMedium priorityJanuary 1, 2027 (effective)
January 1, 2028 (operative: payment condition for items and services furnished on or after this date)
December 31, 2027 (compliance: last day to submit initial attestations for departments already furnishing services when the payment condition starts; the attestation window opened in 2026)
An official source was re-read on November 15, 2026November 8, 2026 edition
Centanafadine Schedule III interim final ruleMedium priorityNovember 30, 2026 (comment deadline)
November 30, 2026: hearing requests and waivers due
An official source was re-read on November 15, 2026November 4, 2026 edition
HHS Section 504 final rule (91 FR 69207)Medium priorityJanuary 4, 2027 (effective)Partly checked; current status not establishedNovember 4, 2026 edition
Medically frail opinion (D. Mass., Commonwealth of Massachusetts v. Oz)Medium priorityJanuary 1, 2027: statutory community engagement requirement begins (per opinion)Partly checked; current status not establishedNovember 4, 2026 edition
OPO conditions for coverage final rule (CMS-3409-F, 91 FR 69390)Medium priorityJanuary 4, 2027 (effective)An official source was re-read on November 15, 2026November 4, 2026 edition
Civil Rights Council pregnancy leave, accommodation and bonding leave regulationsMedium priorityDecember 8, 2026 (comment deadline: 5 p.m.)
December 8, 2026: public hearing beginning 11:00 a.m.
An official source was re-read on November 15, 2026November 4, 2026 edition
DHS final rule removing most automatic EAD renewal extensions (effective 2026-10-14)Medium priorityNone recordedPartly checked; current status not establishedOctober 18, 2026 edition
HHS delegates permissive exclusion authority to CMS while preserving OIG authorityMedium priorityNone recordedAn official source was re-read on November 15, 2026October 18, 2026 edition
FDA final guidance on biosimilar postapproval manufacturing changesMedium priorityNone recordedAn official source was re-read on November 15, 2026October 18, 2026 edition
Federal IDR correcting amendmentMedium priorityNone recordedAn official source was re-read on November 15, 2026October 11, 2026 edition
AB 1760 dentistry changesMedium priorityJanuary 1, 2027 (effective)
January 1, 2028: Previously approved radiation-safety courses keep approval until 2028-01-01 and must reapply to offer courses on or after that date.
An official source was re-read on November 15, 2026October 11, 2026 edition
DMHC APL 26-014Medium priorityJanuary 1, 2027: PBMs must be licensed before this date, as the earlier article reportedFrom the earlier article; not re-verified for this editionOctober 11, 2026 edition
AB 1199 three-year medical-staff reappointment intervalMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 1979 health care chatbot CMIA and clinical-judgment rulesMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 2448 sensitive medical information access controlsMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 2598 hospital and SNF death-notification dutiesMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
CMS SOM Appendix W Transmittal 247 for Critical Access Hospital emergency readinessMedium priorityNone recordedAn official source was re-read on November 15, 2026October 11, 2026 edition
AB 1907 Covered California enrollment options and SAWS intakeMedium priorityJuly 1, 2027 (operative)An official source was re-read on November 15, 2026October 11, 2026 edition
SB 16 county procedures for section 5150 designations, with emergency physicians eligibleMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 1930 Attorney General notice before producing records on legally protected careMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
SB 1023 HIV-prevention antiretroviral product coverage, including dual medical and pharmacy benefitMedium priorityJanuary 1, 2027 (effective: the dual-benefit rule applies to contracts and policies issued, amended or renewed on or after this date, as the earlier article reported and not re-verified)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 2150 employer-paid naloxone training for employees required to certify in CPRMedium priorityJanuary 1, 2027 (effective)Partly checked; current status not establishedOctober 11, 2026 edition
California AG September 25 disability-integration enforcement statementMedium priorityJanuary 4, 2027: No fixed date. Related: HHS Section 504 rule published 2026-11-03, effective 2027-01-04 (already reported in the November 4, 2026 edition).Partly checked; current status not establishedOctober 11, 2026 edition
AB 2011 state mental health parity standardMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
COMPETE Act single-firm public enforcement standardMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 1637 physician-note editing limitsMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 1696 nurse-midwife obstetric emergency supervision exceptionMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
SB 626 perinatal mental-health screening follow-up dutiesMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 2292 bar on administrative fees for disability-benefit certificatesMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
SB 947 automated-decision limits on discipline and terminationMedium priorityJuly 1, 2027 (operative)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 2561 protection of affirmative app privacy settingsMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 2321 Cal/OSHA investigation and inspection-interference changesMedium priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026October 11, 2026 edition
AB 883 data-broker 30-day deletion cycleMedium priorityJanuary 1, 2027 (effective)
July 1, 2027 (operative: public-official and judge notification provisions)
January 1, 2028: independent third-party audits begin, every three years
An official source was re-read on November 15, 2026October 11, 2026 edition
FDA withdrawal of 37 ANDAsMedium priorityNone recordedAn official source was re-read on November 15, 2026October 11, 2026 edition
FDA investigating malignancy risk with Zolgensma and Itvisma gene therapyLower priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
VA and Department of War join TEFCALower priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
FDA revised draft drug-delivery device guidanceLower priorityJanuary 28, 2027: comments by this date ensure FDA considers them before it begins work on the final guidanceAn official source was re-read on November 15, 2026November 4, 2026 edition
EPA Greenhouse Gas Reporting Rule reporting-year 2025 deadline extensionLower priorityMarch 10, 2027 (compliance: extended RY2025 reporting deadline, per title)
November 30, 2026 (comment deadline)
An official source was re-read on November 15, 2026November 4, 2026 edition
FDA hidden-ingredient warningsLower priorityNone recordedAn official source was re-read on November 15, 2026November 4, 2026 edition
Federal IDR batchingLower priorityNone recordedAn official source was re-read on November 15, 2026November 4, 2026 edition
AB 2341 local-agency emergency translation formulaLower priorityJanuary 1, 2027: State survey of a sample of local agencies begins 2027-01-01 and repeats every three years (a state duty). (as the earlier article reported; not re-verified)From the earlier article; not re-verified for this editionOctober 11, 2026 edition
Board of Pharmacy proposes repealing self-assessment regulations, including the Hospital Pharmacy Self-Assessment formLower priorityDecember 7, 2026 (comment deadline: end of the 45-day comment period listed as 2026-10-23 to 2026-12-07)An official source was re-read on November 15, 2026November 8, 2026 edition
Cal/OSHA boiler and pressure-vessel fee increaseLower priorityNone recordedAn official source was re-read on November 15, 2026November 4, 2026 edition
FDA finalizes hepatitis B blood-donation testing guidanceLower priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
CISA, FBI and HHS urge hardening of refrigeration and cold-chain monitoring systemsLower priorityNone recordedAn official source was re-read on November 15, 2026November 8, 2026 edition
Hospital accreditors may survey EMTALA administrative requirements (signage, central log, 5-year transfer records, on-call list) during accreditation surveysLower priorityJanuary 1, 2027 (effective)An official source was re-read on November 15, 2026November 8, 2026 edition
HHS oral-fluid and urine federal workplace drug-testing proposalsLower priorityDecember 28, 2026 (comment deadline)An official source was re-read on November 15, 2026November 4, 2026 edition
Dental Board infection-control (16 CCR 1005) proposalLower priorityNovember 30, 2026 (comment deadline)An official source was re-read on November 15, 2026November 4, 2026 edition
EPA Clean Water Act hazardous substance facility response plans compliance-date delayLower priorityDecember 14, 2026 (effective)An official source was re-read on November 15, 2026November 4, 2026 edition
OPTN donation-after-circulatory-death policyLower priorityNovember 18, 2026: effective date as the earlier article reported it from an HRSA summary, not re-verifiedFrom the earlier article; not re-verified for this editionNovember 4, 2026 edition
FDA requires GLP-1 RA labeling on a potential increased risk of NAIONLower priorityNone recordedPartly checked; current status not establishedNovember 8, 2026 edition
OHCA posts November 18 Board presentationLower priorityNovember 18, 2026: Board meeting 2026-11-18, 10:00 amPartly checked; current status not establishedNovember 8, 2026 edition
FDA eCTD v3.2.2 and v4.0 high-severity validation rejectionsWatchJanuary 16, 2027 (implementation)An official source was re-read on November 15, 2026November 4, 2026 edition
FDA rare-disease framework request for informationWatchDecember 11, 2026 (comment deadline)An official source was re-read on November 15, 2026November 4, 2026 edition
FDA lot-level food traceability meetingWatchDecember 6, 2026 (comment deadline: electronic comments until 11:59 p.m. Eastern Time that day, paper comments if received by that date)An official source was re-read on November 15, 2026November 4, 2026 edition
AB 1018 automated decision systemsWatchNone recordedAn official source was re-read on November 15, 2026October 11, 2026 edition

No longer carried

Items no longer carried (3)
ItemPriorityDates still aheadWhy it leaves the listEarlier article
DOJ action highlights remote IT-worker identity risks for health care employersMedium priorityNone recordedJustice Department release of October 13, 2026, more than 30 days old with no dated step recorded aheadOctober 18, 2026 edition
HHS draft 503A peptide enforcement-discretion policyMedium priorityNone recordedThe date it carried has passed, or the earlier record marked it completeNovember 4, 2026 edition
USCIS proposal removing deference to prior I-129 eligibility determinationsLower priorityNone recordedThe date it carried has passed, or the earlier record marked it completeNovember 4, 2026 edition

Earlier developments first reported here

OHCA amended material change transaction rules took effect November 2; HCAI posts filing flowchart for management services organizations

Medium priorityNew in this editionRead article →

What changed

The laws and regulations page of the Department of Health Care Access and Information (HCAI) states that the Office of Administrative Law approved amendments to the Office of Health Care Affordability (OHCA) Material Change Transactions and Pre-Transaction Review regulations, used for cost and market impact review (CMIR), on October 2, 2026, with a November 2, 2026 effective date (California Code of Regulations, title 22, sections 97431 through 97442). On November 10, 2026, HCAI posted a flowchart, marked New 11/2026, on when a management services organization (MSO) must file a material change transaction notice; it says it was developed for the regulations effective November 2, 2026. Under the flowchart, one threshold is an MSO owned by a hospital with one or more physician organization clients or affiliates. The approved text requires a health care entity or noticing entity that meets the filing criteria to give OHCA notice at least 90 days before the closing date of the transaction.

Background

OHCA adopted emergency regulations to implement the Health Care Market Oversight Program, under which entities file notices of material change transactions and OHCA may conduct a cost and market impact review. OHCA's FAQ lists management services organizations among noticing entities, alongside private equity groups and hedge funds.

Who this affects

Hospitals and health systems that own a management services organization with physician organization clients or affiliates, and any health care entity or management services organization planning a merger, acquisition, affiliation or transfer of control in California.

Why it matters

Under the regulations effective November 2, 2026, a hospital-owned MSO that meets a threshold and is party to a covered transaction must give notice at least 90 days before closing. Inference: transaction timelines involving hospital MSOs and physician groups need that lead time. Transactions in the usual course of business, or among parties already under common control, fall outside the definition.

Required actions

  • A health care entity or noticing entity that meets the filing criteria must give OHCA notice of a material change transaction at least 90 days before the closing date (California Code of Regulations, title 22, section 97435(a), effective November 2, 2026).

Recommended action

  • Inventory MSOs owned by or affiliated with the hospital and test each against the thresholds in the HCAI flowchart.
  • Add the 90-day OHCA notice step to the transaction checklist for physician group and MSO deals.

Implementation playbook

  1. List the MSOs owned by or affiliated with the hospital and test each against the thresholds in the HCAI flowchart. Owner: Legal and Compliance. Due: 2026-12-15.
  2. Add the 90-day OHCA notice step to the checklist for physician group and MSO transactions, and recheck the planned closing dates of deals already in progress. Owner: Strategy and business development with Legal. Due: 2026-11-30.

Scope and timing

Authority status
Effective (emergency regulations)
Responsible owner
Legal; Strategy and business development; Compliance
Effective date
2026-11-02
Other dates
2026-10-02: approved by the Office of Administrative Law; 2026-11-10: HCAI document record date for the MSO flowchart

Not established

Which provisions are new in the November 2 amendments was not established, because the approved text's strikeout and underline marks do not survive text extraction. The expiry date of the emergency regulations was not established.

Sources

California regulator tells health plans how downcoding must be disclosed and reviewed, with plan filings due November 23

Medium priorityNew in this editionRead article →

What changed

On October 23, 2026, the California Department of Managed Health Care (DMHC) issued All Plan Letter (APL) 26-015 to all licensed health care service plans on downcoding, which the letter defines as paying a claim at a less complex or lower level of service than the provider billed. Plans must disclose the criteria and methods they use to pick claims for downcoding and to set the adjusted level, must review all supplemental documentation the provider submitted, which may include medical records, before downcoding, and must pay the portion of a claim the documentation supports. Each plan that has implemented or seeks to implement downcoding must make one compliance filing with DMHC by November 23, 2026.

Background

The Knox-Keene Act and DMHC's claims rules (California Code of Regulations, title 28, Rule 1300.71) require plans to pay a complete claim within 30 calendar days, to disclose their payment policies and coding methods to providers on written request, and to tell providers how to dispute a claim adjustment. The letter says downcoding is not expressly prohibited by the Act, and applies those existing rules to it.

Who this affects

Hospitals, physician groups and other providers that bill health plans licensed by the California Department of Managed Health Care (DMHC), their revenue-cycle, coding and managed-care contracting teams, and medical groups that adjudicate claims as a plan's delegate.

Why it matters

Providers gain a stated basis to ask each DMHC-licensed plan for its downcoding criteria, to expect the plan to read submitted records before reducing a claim level, and to expect payment of the supported portion instead of a whole-claim withhold. For providers acting only as submitting providers the letter adds no duty; an entity that adjudicates claims as a plan's delegate falls under the plan's responsibility for its delegates' compliance. The plan filings are not public in this letter, so how individual plans respond was not established.

Required actions

  • Health plans that have implemented or seek to implement downcoding: submit one eFiling, an Amendment titled APL 26-015 Downcoding Compliance, to DMHC by November 23, 2026.
  • Medical groups and other entities that adjudicate claims as a plan's delegate: the plan remains responsible for ensuring that they comply with the letter.

Recommended action

  • Ask each DMHC-licensed plan, in writing, for the payment policies, rules and coding methods it uses for downcoding, as Rule 1300.71(o)(2) provides.
  • Track claims paid at a lower level than billed by plan, and use the plan's provider dispute process with supporting documentation where the record supports the billed level.
  • If your organization adjudicates claims as a plan's delegate, compare your own level-of-service adjustments with the letter, since the plan remains responsible for its delegates' compliance.

Scope and timing

Authority status
Guidance
Responsible owner
Revenue Cycle; Coding; Managed Care Contracting
Publication date
2026-10-23
Compliance date
2026-11-23
Other dates
November 23, 2026 is the date for each plan's compliance filing to DMHC; the letter sets no date for providers.

Not established

How individual plans responded in their filings was not established. The letter does not say whether it applies to Medi-Cal managed care plans' delegated claims in any different way.

Sources

CMS revises QSO-25-04-Transplant: initial transplant program surveys may proceed on raw outcome data while the final SRTR comparison is pending

Lower priorityNew in this edition

What changed

On October 30, 2026, the Centers for Medicare & Medicaid Services (CMS) revised survey memo QSO-25-04-Transplant (Quality, Safety and Oversight) on outcome requirements for initial transplant program approval. CMS may now use raw 1-year patient and graft survival data from the Scientific Registry of Transplant Recipients (SRTR) to assess likely compliance, and the state survey agency may survey the other conditions of participation while holding the outcome determination open until the SRTR report is published. If the published report shows compliance, CMS may set the effective date of certification so the program is not penalized for the reporting lag; if it shows non-compliance, CMS denies initial approval. The flexibility is case by case and does not change the underlying requirements.

Who this affects

Hospitals seeking initial Medicare approval of a new solid organ transplant program (intestine and pancreas programs are exempt from the outcome requirements).

Why it matters

A hospital opening a transplant program may be able to complete its initial survey earlier and obtain an earlier certification effective date, shortening the period in which it performs transplants before Medicare approval. Final approval still depends on the published outcome data.

Recommended action

  • Hospitals with a transplant program awaiting or planning initial Medicare approval should review the revised memo with their survey and transplant administration teams.

Scope and timing

Authority status
Guidance
Responsible owner
Regulatory Compliance (transplant administration)
Publication date
2026-10-30 (memo revision date)
Effective date
Immediately, as the memo states (memo dated 2026-10-30)
Other dates
Original memo released 2024-10-10

Not established

Whether State Operations Manual Chapter 2 was revised to match was not checked.

Sources

CDC MMWR reports cutaneous aspergillosis clusters among extremely preterm infants in two NICUs

Lower priorityNew in this edition

What changed

The Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) of November 5, 2026 describes two clusters of cutaneous aspergillosis detected during 2023-2024 in neonatal intensive care units (NICUs) in Michigan (two patients, including one death) and New York (three patients, no deaths). No definitive source was identified; the investigations prompted improvements in linen handling, air-handling measures and infection prevention practices.

Who this affects

Hospitals with neonatal intensive care units, and their infection prevention, neonatology and facilities engineering teams.

Why it matters

The report asks clinicians to consider cutaneous aspergillosis in extremely preterm neonates with skin lesions, and points to coordinated assessment by clinicians, infection preventionists and facility engineers.

Scope and timing

Authority status
Public health report
Responsible owner
Infection Prevention; Neonatology; Facilities
Publication date
2026-11-05

Not established

Only the Summary box was captured; the full report text was not read.

Sources

Forward horizon

0 to 30 days

31 to 60 days

61 to 90 days

Beyond 90 days

Coverage limitations

Triggered sources. Each triggered source has a recorded relevance decision. Reviewed this week include FDA recalls and early alerts (the FDA drug shortage pages and the compounding warning-letter search were not read), the Health Resources and Services Administration (HRSA) and the organ transplant network, CDC health alerts and the Morbidity and Mortality Weekly Report (MMWR), HHS appeals board decisions (the Medicare Appeals Council index returned Page Not Found), the Administration for Strategic Preparedness and Response (ASPR), the Equal Employment Opportunity Commission (EEOC), the National Labor Relations Board (NLRB), USCIS (U.S. Citizenship and Immigration Services), IRS, the federal Occupational Safety and Health Administration (OSHA), the Environmental Protection Agency (EPA), the Nuclear Regulatory Commission (NRC), the USITC (U.S. International Trade Commission) and several California boards and departments. Partly covered: DEA, the Substance Abuse and Mental Health Services Administration (SAMHSA) and 42 CFR Part 2, HHS cybersecurity products, court opinions, accreditors, Agency for Healthcare Research and Quality (AHRQ) patient safety organizations, the Medical Board and the Board of Registered Nursing, the Health Plan Management System (HPMS) and the Office of Refugee Resettlement. Not reached: the Labor Department, the Federal Communications Commission (FCC), the federal emergency medical services (EMS) office, notices of the California Emergency Medical Services Authority (EMSA) and the Department of Toxic Substances Control (DTSC).

Sources that need a person. A few sources stopped at a human-verification check or a security challenge and were not worked around: a state license search, some U.S. Attorney release pages for carried enforcement items, Justice Department speech and news listings, the Joint Commission news pages and the DTSC newsroom. Carried items that depend on those pages say what their statements rest on.

How claims were checked. Every quoted passage behind a statement was checked against a saved copy of the source document it came from. Some sources could be read only in a browser; those statements rest on a text capture of the page rather than the original document.

Closing statement. Finished with coverage gaps. Not complete this week: HHS and Office for Civil Rights (OCR) FAQ entries; Justice Department speeches and Justice Manual revisions; CMS Innovation Center bulletins; State Public Health Officer orders, news from the California Department of Industrial Relations (DIR) and EMSA notices; Medicare Learning Network (MLN) Matters Special Editions not tied to a change request; Medicare coverage records after November 6, Quality Payment Program (QPP) announcements and the Comprehensive Error Rate Testing (CERT), Program for Evaluating Payment Patterns Electronic Report (PEPPER) and Unified Program Integrity Contractor (UPIC) channels; California approval lists on Medicaid.gov and dates of pending state plan amendments; Department of Health Care Services (DHCS) rate, Hospital Quality Assurance Fee (HQAF) and directed-payment notices and enrollment notices; DHCS audit postings; CMS Administrator decisions; and Office of Administrative Law (OAL) recent actions. Each is searched again next week.

Source families

  • Federal Register (Reviewed): Every document published 2026-11-01 to 2026-11-14 (the window and the reopened week) was listed through the Federal Register API and screened, agency by agency (58 ledger rows).
  • HHS and OCR (Partial): Read in the browser: HHS press room and OCR newsroom, OCR guidance pages, HRSA news, 340B program updates and program-integrity pages, and OPTN at its new hrsa.gov address. Not done: individual OCR FAQ entries were not opened, so an FAQ revision dated in the window is not ruled out. hhs.gov refuses direct requests.
  • HHS OIG (Reviewed): What's New, reports and publications by issue date, advisory opinions, compliance guidance, alerts, FAQs, news releases and the work plan checked for the window.
  • Justice Department policy (Partial): Main Justice policy releases screened through the press release API. Not done: the speeches listing (a human-verification check, no API) and a Justice Manual revision list (none exists; seven healthcare-relevant titles read, none revised in November 2026).
  • CMS (Partial): Federal Register and public inspection, CMS rules and guidance, SMD 26-006 (read in the browser) and the Innovation Center models page and dataset were checked. Not done: Innovation Center email bulletins (the GovDelivery archive redirects to a sign-in page) and what changed on model pages that carry no modified date.
  • ASTP/ONC (Reviewed): ONC newsroom, blog, news releases, the healthit.gov content API for items published or modified in the window, and the regulation, information blocking and certification pages.
  • FTC (Reviewed): FTC press releases for the window and cases and proceedings read in the browser; the three FTC Federal Register documents in the window screened.
  • California Legislature (Reviewed): All five checks done in the browser: bill search with a control search for the date filter, Assembly and Senate floor actions from that result set, the official history of each measure found, and the Governor's newsroom for the month.
  • California regulators (Partial): DMHC all-plan letters and rulemaking (browser), CDPH letters and news, HCAI and OHCA, OAL Notice Register, the Standards Board, Medical Board and BRN, CDSS and DTSC were checked. Not done: the index of State Public Health Officer orders was not located; DIR press releases (both addresses return 404); EMSA has no notices list on its new site.
  • CMS newsroom (Reviewed): The dated Newsroom Articles listing covers every article type for the window, and each relevant release was read. The newsroom search page refuses direct requests and was not needed.
  • MLN Connects (Partial): The MLN Connects newsletter index and the November 12 edition, and MLN Matters articles tied to change requests, were checked. Not done: Special Edition articles not tied to a change request have no dated index, so their absence is not proven.
  • CMS transmittals (Reviewed): The 2026 transmittals index was read for the window and each new transmittal opened.
  • Medicare manuals and coverage (Partial): Medicare Coverage Database reports, Cotiviti RAC approved issues (newest July 9, 2026) and Palmetto MolDX news (newest October 9) were checked. Not done: the MCD data ends November 6, so LCDs and articles dated November 7 to 14 are rechecked next run; QPP announcements and listserv messages; the CERT contractor site; the PEPPER portal (sign-in); no dated UPIC listing exists.
  • Medicare Advantage and D-SNP (Reviewed): CMS newsroom dated list and RSS, the D-SNP, rate announcement and bid pages, and the Part C and D enforcement actions table.
  • Medicaid and CHIP (Partial): Medicaid.gov policy guidance and New and Notable, SMD 26-006, the program-integrity page and the DHCS approved SPA list (SPA 26-0020 approved November 5) were read in the browser. Not done: the DHCS pending SPA list prints no dates, and the medicaid.gov California SPA and waiver approval lists were not read.
  • Noridian (Medicare contractor) (Reviewed): Noridian JE Part A and Part B latest updates, articles posted in the window, proposed LCDs, MolDX and Review Choice Demonstration pages; Palmetto MolDX news read in the browser.
  • DHCS (Partial): Read in the browser: managed care APLs, BHINs, news, stakeholder news, CalAIM, the ORP page and deck, SPA lists, Medi-Cal provider news and Medi-Cal Rx bulletins. Not done: HQAF, rates, DSH and directed-payment notices (the HQAF address returns Page not found), provider enrollment and PAVE notices (block page and sign-in), PED pages, and the legacy Medi-Cal newsroom host (unreachable).
  • OIG enforcement (Reviewed): OIG enforcement actions by type and entry page, including the listings OIG's What's New page shows as updated on November 13, 2026, and the CIA browse list with the rolling 90-day view.
  • Justice Department healthcare releases (Reviewed): Every Justice Department and U.S. Attorney press release dated in the window was retrieved through the official press release API and screened. The web listings sit behind a bot check, so the API set could not be cross-checked against them.
  • OCR enforcement (Reviewed): OCR resolution agreements and civil money penalties page and the OCR newsroom read in the browser for the window.
  • FTC health privacy (Reviewed): FTC press releases and the cases and proceedings pages for existing health-privacy matters read in the browser.
  • California enforcement (Partial): DMHC enforcement search with a control search, DMHC press releases, Attorney General releases, the separate Medi-Cal fraud division search and the CDPH enforcement export were checked. Not done: DHCS audit publications; the audits pages render but print no dates for their reports.
  • cms-qso (Reviewed): QSO policy memos for the window, the revised QSO-25-04 transplant memo, and State Operations Manual transmittals.
  • hospital-quality (Reviewed): QualityNet news read in the browser: newest article September 24, 2026, none in the window.
  • cms-price-transparency (Reviewed): The civil money penalty notices list, main page and enforcement activities dataset.
  • prrb-admin (Partial): PRRB decisions 2026-D30 to D34, jurisdictional decisions and alerts were read. Not done: the CMS Administrator decisions listing prints no dates and is not in date order, so decisions issued in the window cannot be identified; the listing is kept for comparison next run.
  • dhcs-eligibility (Reviewed): The 2026 ACWDL and MEDIL lists read in the browser: newest ACWDL 26-22 (October 27); MEDILs I 26-29 to 33 (October 29 to November 4), none from November 8 to 14.
  • oal-actions (Partial): Emergency regulations under review were read. Not done: the Recent Actions table gives no action dates or outcomes, so actions taken in the window (including the two OHCA readopts) are checked against Notice Register 47-Z next run.
  • ca-pharmacy (Reviewed): Pending regulations (no step in the window), alerts, the news archive and the October to December disciplinary list (no facility action; one individual decision in the window) were read.
  • hcai-facilities (Reviewed): HCAI building safety codes and documents modified in the window, and the Hospital Fair Billing Program laws, regulations and policy pages.

Privacy preferences

Where enabled for this site, Cloudflare Web Analytics can send page-use and performance measurements to Cloudflare. This panel provides information and does not turn analytics on or off.

This panel stores no tracking choice and does not change your tool saves, screening, resets, reports or exports. Other sites have separate settings.

Read Privacy & Cookies